Daraxonrasib
Daraxonrasib, sold under the brand name Rasonque, is an anti-cancer medication used for the treatment of pancreatic cancer.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Daraxonrasib, sold under the brand name Rasonque, is an anti-cancer medication used for the treatment of pancreatic cancer. It is an inhibitor of the RAS GTPase family. It is an orally administered small molecule pan-RAS inhibitor.
It was developed by Revolution Medicines. It inhibits all three key members of the Ras superfamily: KRAS, HRAS, and NRAS. The three RAS proteins are GTPases that become active when bound to GTP but normally convert this GTP to GDP and thereby become inactive.
RAS proteins that are bound to GDP and GTP are termed respectively RAS(OFF) and RAS(ON). Daraxonrasib targets RAS in the ON state, but not in the OFF state. Daraxonrasib was approved for medical use in the United States in August 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378158980 under CC BY-SA 4.0; modifications have been made.